Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis

European Journal of Cancer

Volumn 46, Issue 4, 2010, Pages 744-751

  Kuo, Yuan Hung ^a   Lu, Sheng Nan ^a   Chen, Chao Long ^b   Cheng, Yu Fan ^b   Lin, Chih Yun ^a   Hung, Chao Hung ^a   Chen, Chien Hung ^a   Changchien, Chi Sin ^a   Hsu, Hsuan Chih ^b   Hu, Tsung Hui ^a   Lee, Chuan Mo ^a   Wang, Jing Houng ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Surveillance; Survival; Treatment guidelines

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; IODINATED POPPYSEED OIL; TAMOXIFEN;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER EPIDEMIOLOGY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; EARLY DIAGNOSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION;

AGED; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POPULATION SURVEILLANCE; TREATMENT OUTCOME;

EID: 76049113547     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.018     Document Type: Article

References (35)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. Department of Health: Health statistics, 2004. Taipei, Department of Health, Executive Yuan, Republic of China; 2007.
3. Carr B.I. Hepatocellular carcinoma: current management and further trends. Gastroenterology 127 (2004) S218-S224
4. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL Conference. J Hepatol 35 (2001) 421-430
5. Changchien C.S., Chen C.L., Yen Y.H., et al. Analysis of 6381 hepatocellular carcinoma patients in Southern Taiwan: prognostic features, treatment outcome and survival. J Gastroenterol 43 (2008) 159-170
6. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
7. Bruix J., and Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
8. Kudo M., and Okanoue T. Japan Society of Hepatology Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 72 (2007) 2-15
9. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut 48 (2001) 251-259
10. Ando E., Kuromatsu R., Tanaka M., et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol 40 (2006) 942-948
11. Lu S.N., Wang J.H., Liu S.L., et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 107 (2006) 2212-2222
12. Dibisceglie A.M. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 1275 (2004) 104-107
13. Befeler A.S., and Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122 (2002) 1609-1619
14. Cillo U., Vitale A., Grigoletto F., et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44 (2006) 723-731
15. Wang J.H., Changchien C.S., Hu T.H., et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - survival analysis of 3892 patients. Eur J Cancer 40 (2008) 1000-1006
16. Trevisani F., Magini G., Santi V., et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol 102 (2007) 1022-1031
17. Kee K.M., Wang J.H., Lee C.M., et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5613 cased from a medical center in southern Taiwan. Int J Cancer 120 (2007) 2650-2655
18. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999) 329-338
19. Cheng Y.F., Kan Z., Chen C.L., et al. Efficacy and safety of preoperative lobar or segmental ablation via transarterial administration of ethiodol and ethanol mixture for treatment of hepatocellular carcinoma: clinical study. World J Surg 24 (2000) 844-850
20. Trevisani F., De N.S., Rapaccini G., et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97 (2002) 734-744
21. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 417-422
22. Chen J.G., Parkin D.M., Chen Q.G., et al. Screening for liver cancer: results of a randomized controlled trial in Qidong China. J Med Screen 10 (2003) 204-209
23. Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int 29 (2009) 143-147
24. Patel D., Terrault N.A., Yao F.Y., Bass N.M., and Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 3 (2005) 75-84
25. Nouso K., Tanaka H., Uematsu S., et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 23 (2008) 437-444
26. Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 47 (2008) 82-89
27. Lau W.Y., and Lai E.C. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 249 (2009) 20-25
28. Lin S.M., Lin C.J., Lin C.C., Hsu C.W., and Chen Y.C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology 127 (2004) 1714-1723
29. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 (2005) 122-130
30. Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228 (2003) 235-240
31. Poon R.T., Ng K.K., Lam C.M., et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of Initial 100 patients in a tertiary institution. Ann Surg 239 (2004) 441-449
32. Stravitz R.T., Heuman D.M., Chand N., et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 121 (2008) 119-126
33. Toyoda H., Kumada T., Kiriyama S., et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin Gastroenterol Hepatol 4 (2006) 1170-1176
34. Chan A.C., Poon R.T., Ng K.K., et al. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 247 (2008) 666-673
35. Kemp W., Pianko S., Nguyen S., Bailey M.J., and Roberts S.K. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol 20 (2005) 873-881